In the past three fiscal years, McCormick has returned more than $1.0 billion to its shareholders in the form of dividends and share buybacks.
McCormick expects sales to rise 5.0%–7.0% for fiscal 2017 on a currency neutral basis. That’s in line or slightly above its long-term projection.
Despite a slow-growth scenario in the food industry, McCormick has driven sales through strategic acquisitions and price restructuring.
McCormick stock has risen about 7.2% YTD as of April 6, 2017, reflecting the company’s ability to drive sales despite a softness in the industry.
Wall Street’s reaction to WBA’s second quarter results While Walgreens (WBA) delivered mixed 2Q17 results, CEO (chief executive officer) Stefano Pessina’s optimism about the pending Rite Aid (RAD) deal has…
Walgreens (WBA) reported mixed results on April 5, and its share price dropped 1.6% that day. It’s now trading 7.8% below its 52-week high price.
WBA’s CEO, Stefano Pessina, said that he remains positive about the Rite Aid deal, which has been waiting for FTC approval for more than a year.
On April 5, 2017, WBA reported in-line earnings for fiscal 2Q17. Its EPS grew 3.8% YoY to $1.36.
WBA’s Retail Pharmacy USA division, which accounted for ~74% of the company’s top line in 2Q17, reported a 1.5% YoY rise.
WBA’s Retail Pharmacy International segment’s sales fell 14.5% YoY to $3.1 billion, primarily due to currency headwinds and weakness in UK pharmacy sales.
For the first sixth months of fiscal 2017, WBA sales plunged 2.1% YoY to $57.9 billion. On a currency-neutral basis, however, sales rose 1% YoY.
WBA’s fiscal 2Q17 EPS stood at $1.36, in line with estimates. Its top line, however, missed the consensus estimate, falling 2.4% YoY to ~$29.5 billion.
Of the 32 analysts covering Costco (COST), 69.0% have rated the stock as a “buy” as of April 5. The stock has been rated as a “hold” by 31% of these analysts.
Costco (COST) stock started off 2017 with a decent performance—until it announced the fiscal 2Q17 (ended February 12, 2017) results.
Despite its challenging operating environment, Costco (COST) reported strong sales in March, with comparable-store sales, or comps, rising 6.0%.
On March 31, 2017, Constellation Brands (STZ) was trading at a 12-month forward PE (price-to-earnings multiple) of 22.2x.
On March 31, 2017, 12 out of 18 analysts had “buy” ratings on Constellation Brands (STZ) stock. Six analysts had “hold” ratings on the stock, and no analysts had “sell” ratings on the stock.
In its fiscal 3Q17, which ended on November 30, 2016, the company delivered adjusted EPS of $1.96, surpassing analysts’ consensus estimate of $1.72.
Constellation Brands (STZ) delivered sales rises of 14.7%, 16.6%, and 10.4% in fiscals 1Q17, 2Q17, and 3Q17, respectively.
Constellation Brands (STZ) is slated to announce its fiscal 4Q17 and fiscal 2017 results on April 6, 2017. The company’s fiscal 4Q17 ended on February 28, 2017.